PL2780717T3 - Oznaczenia adrenomeduliny i sposoby do oznaczania dojrzałej adrenomeduliny - Google Patents

Oznaczenia adrenomeduliny i sposoby do oznaczania dojrzałej adrenomeduliny

Info

Publication number: PL2780717T3
Authority: PL; Poland
Prior art keywords: adrenomedullin; assays; methods; determining mature; determining
Prior art date: 2011-11-16

Application number

PL12791143T

Other languages

English (en)

Inventor

Andreas Bergmann

Original Assignee

Sphingotec Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-16

Filing date

2012-11-16

Publication date

2017-06-30

2012-11-16 Application filed by Sphingotec Gmbh filed Critical Sphingotec Gmbh

2017-06-30 Publication of PL2780717T3 publication Critical patent/PL2780717T3/pl

Links

102000004379 Adrenomedullin Human genes 0.000 title 2
101800004616 Adrenomedullin Proteins 0.000 title 2
ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 title 2
238000003556 assay Methods 0.000 title 1
238000000034 method Methods 0.000 title 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Organic Chemistry (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Physics & Mathematics (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Marine Sciences & Fisheries (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)

PL12791143T 2011-11-16 2012-11-16 Oznaczenia adrenomeduliny i sposoby do oznaczania dojrzałej adrenomeduliny PL2780717T3 (pl)

Applications Claiming Priority (12)

Application Number	Priority Date	Filing Date	Title
EP11189447		2011-11-16
EP11189452		2011-11-16
EP11189448		2011-11-16
EP11189450		2011-11-16
EP11189449		2011-11-16
EP12160018		2012-03-16
EP12160015		2012-03-16
EP12160014		2012-03-16
EP12160016		2012-03-16
EP12160017		2012-03-16
EP12186449		2012-09-27
EP12791143.6A EP2780717B1 (en)	2011-11-16	2012-11-16	Adrenomedullin assays and methods for determining mature adrenomedullin

Publications (1)

Publication Number	Publication Date
PL2780717T3 true PL2780717T3 (pl)	2017-06-30

Family

ID=47148677

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL12791143T PL2780717T3 (pl)	2011-11-16	2012-11-16	Oznaczenia adrenomeduliny i sposoby do oznaczania dojrzałej adrenomeduliny

Country Status (16)

Country	Link
US (4)	US9535060B2 (pl)
EP (1)	EP2780717B1 (pl)
JP (1)	JP6336911B2 (pl)
CN (1)	CN104067130B (pl)
DK (1)	DK2780717T3 (pl)
ES (1)	ES2617211T3 (pl)
HK (1)	HK1202624A1 (pl)
HR (1)	HRP20170427T1 (pl)
HU (1)	HUE032648T2 (pl)
MY (5)	MY178654A (pl)
PL (1)	PL2780717T3 (pl)
PT (1)	PT2780717T (pl)
RS (1)	RS55804B1 (pl)
RU (1)	RU2657517C2 (pl)
SI (1)	SI2780717T1 (pl)
WO (1)	WO2013072509A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT3553084T (lt)	2011-11-16	2023-03-10	Adrenomed Ag	Anti-adrenomedulino (adm) antikūnas arba anti-adm antikūno fragmentas, arba anti-adm ne-ig karkasas, skirtas organų funkcijos sutrikimo arba organų nepakankamumo profilaktikai arba sumažinimui paciento, sergančio lėtine arba ūmine liga arba esančio ūminės būklės, organizme
AU2012338733B2 (en)	2011-11-16	2017-08-24	Adrenomed Ag	Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
PT2780371T (pt)	2011-11-16	2019-01-30	Adrenomed Ag	Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm para a regulação do equilíbrio de fluidos num doente com uma doença aguda ou crónica
KR101548284B1 (ko) *	2014-05-23	2015-08-28	주식회사 나노엔텍	신규한 시료 내 검출대상물의 검출방법 및 그를 이용한 검출키트
JP6944449B2 (ja) *	2015-11-27	2021-10-06	ベー．エル．アー．ハー．エム．エスゲゼルシャフトミットベシュレンクテルハフツング	対象の細胞外液量状態のマーカーとしてのＭＲ−ｐｒｏＡＤＭ
RU2764766C2 (ru) *	2016-08-09	2022-01-21	Б.Р.А.Х.М.С. Гмбх	Гистоны и/или proadm в качестве маркеров, свидетельствующих об органной дисфункции
EP3309550A1 (en) *	2016-10-12	2018-04-18	sphingotec GmbH	Method for the detection of apolipoprotein e4
EP3555130A1 (en) *	2016-12-16	2019-10-23	AdrenoMed AG	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
JP6862963B2 (ja) *	2017-03-17	2021-04-21	東ソー株式会社	ペプチドの吸着抑制剤
WO2018216580A1 (ja) *	2017-05-22	2018-11-29	東ソー株式会社	アドレノメデュリン濃度変動による予後予測の情報提供方法及びその試薬
EP3682245A1 (en) *	2017-09-13	2020-07-22	B.R.A.H.M.S GmbH	Pro-adm as a therapy monitoring marker for critcally ill patients
JP7291688B2 (ja) *	2017-09-13	2023-06-15	ベー．エル．アー．ハー．エム．エスゲゼルシャフトミットベシュレンクテルハフツング	重篤患者における腎置換療法のための指標としてのアドレノメズリン前駆体
CN111511390B (zh) *	2017-09-25	2024-09-20	艾德里诺医药公司	用于治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂
US20220268761A1 (en)	2017-10-18	2022-08-25	Adrenomed Ag	Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
BR112020014940A2 (pt) *	2018-02-08	2020-12-08	Sphingotec Gmbh	Adrenomedulina (adm) para diagnóstico e/ou predição de demência e ligante antiadrenomedulina para uso em terapia e prevenção de demência
US20210155680A1 (en) *	2018-02-27	2021-05-27	Shimadzu Corporation	ANTIBODY THAT SPECIFICALLY RECOGNIZES N TERMINUS OF APP669-x, AND IMMUNOASSAY METHOD
WO2019167128A1 (ja) *	2018-02-27	2019-09-06	株式会社島津製作所	サンドイッチ型免疫測定法
EP3608673A1 (en) *	2018-08-08	2020-02-12	B.R.A.H.M.S GmbH	Pro-adm for prognosing the risk of a medical condition requiring hospitalization in patients with symptoms of infectious disease
CN113597429A (zh) *	2019-03-01	2021-11-02	株式会社岛津制作所	App669-711测定方法及测定用试剂盒
CN110470771B (zh) *	2019-09-05	2021-06-01	清华大学	一种评价转基因植物食用安全性的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en)	1988-08-01	1993-03-04	Ciba Corning Diagnostics Corp.	Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
WO1991010741A1 (en)	1990-01-12	1991-07-25	Cell Genesys, Inc.	Generation of xenogeneic antibodies
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
EP0585287B1 (en)	1990-07-10	1999-10-13	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
WO1993012227A1 (en)	1991-12-17	1993-06-24	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
JP2774769B2 (ja)	1993-04-26	1998-07-09	賢治寒川	アドレノメデュリン
US6320022B1 (en)	1995-08-18	2001-11-20	The United States Of America As Represented By The Department Of Health And Human Services	Adrenomedullin peptides
CA2242308A1 (en)	1997-12-08	1999-06-08	Smithkline Beecham Laboratoires Pharmaceutiques	Novel compounds
DE19847690A1 (de)	1998-10-15	2000-04-20	Brahms Diagnostica Gmbh	Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
US6818418B1 (en)	1998-12-10	2004-11-16	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
ATE313802T1 (de)	1999-09-10	2006-01-15	Us Gov Health & Human Serv	Bestimmung von adrenomedullin-bindenden proteinen
AU2002305394A1 (en)	2001-05-04	2002-11-18	Biosite, Inc.	Diagnostic markers of acute coronary syndromes and methods of use thereof
RU2209071C2 (ru) *	2001-08-08	2003-07-27	Ростовский НИИ акушерства и педиатрии	Способ лечения сепсиса у детей
JP2005508623A (ja)	2001-08-30	2005-04-07	バイオレクシスファーマシューティカルコーポレイション	改変されたトランスフェリン融合タンパク質
US6864237B2 (en)	2002-05-17	2005-03-08	Ping Wang	Treatment of shock using adrenomedullin and adrenomedullin binding protein-1
DK2298278T3 (en)	2002-06-07	2016-02-01	Dyax Corp	Prevention and reduction of blood loss and inflammatory response
DE10316583A1 (de)	2003-04-10	2004-10-28	B.R.A.H.M.S Aktiengesellschaft	Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
JP2007523844A (ja)	2003-04-25	2007-08-23	ジェノバ・リミテッド	心臓血管障害において減少する分泌ポリペプチド種
US6884781B2 (en)	2003-05-16	2005-04-26	Ping Wang	Treatment of shock using adrenomedullin binding protein-1
JP2007518062A (ja) *	2003-09-29	2007-07-05	バイオサイトインコーポレイテッド	敗血症を診断する方法および診断するための組成物
WO2005040229A2 (en)	2003-10-24	2005-05-06	Avidia, Inc.	Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en)	2004-02-23	2010-02-04	Anaphore, Inc.	Tetranectin Trimerizing Polypeptides
US20070280886A1 (en)	2004-09-09	2007-12-06	Bayer Healthcare Ag	Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr)
US8278262B2 (en)	2004-09-21	2012-10-02	Biontech Ag	Use of microproteins as tryptase inhibitors
US9829494B2 (en)	2005-12-01	2017-11-28	Adrenomed Ag	Methods of treatment using ADM antibodies
US7993832B2 (en) *	2006-08-14	2011-08-09	Xdx, Inc.	Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
EP2231860B1 (en)	2007-12-19	2011-10-05	Affibody AB	Polypeptide derived from protein a and able to bind pdgf
CN107011425B (zh)	2008-11-03	2021-01-01	分子组合公司	抑制vegf-a受体相互作用的结合蛋白
CA2772162C (en)	2009-08-27	2018-05-22	Covagen Ag	Anti-il-17a fynomers and medical uses thereof
EP2379581B1 (en)	2009-12-14	2013-10-09	Scil Proteins GmbH	A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands
DE102010040035A1 (de)	2010-03-04	2011-09-08	Robert Bosch Gmbh	Verbesserungen der Rückwärts-Analyse zur Bestimmung von Fehlermaskierungsfaktoren
WO2011127176A2 (en)	2010-04-06	2011-10-13	The Children's Research Institute	Methods for treating or screening for compounds for the treatment of sepsis
ES2552954T3 (es)	2010-04-30	2015-12-03	Alexion Pharmaceuticals, Inc.	Anticuerpos anti-C5a y métodos para el uso de los anticuerpos
RU2569745C2 (ru)	2010-06-08	2015-11-27	Пиерис АГ	Мутеины липокалина слезы, связывающие альфа il-4 r
FR2964103B1 (fr) *	2010-08-30	2018-11-23	Universite D'aix-Marseille	Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament
US11067586B2 (en) *	2011-11-16	2021-07-20	Sphingotec Gmbh	Adrenomedullin assays and methods for determining mature adrenomedullin

2012
- 2012-11-16 MY MYPI2014001418A patent/MY178654A/en unknown
- 2012-11-16 MY MYPI2014001421A patent/MY175997A/en unknown
- 2012-11-16 HU HUE12791143A patent/HUE032648T2/en unknown
- 2012-11-16 MY MYPI2014001422A patent/MY192113A/en unknown
- 2012-11-16 WO PCT/EP2012/072928 patent/WO2013072509A1/en active Application Filing
- 2012-11-16 MY MYPI2014001420A patent/MY174877A/en unknown
- 2012-11-16 PL PL12791143T patent/PL2780717T3/pl unknown
- 2012-11-16 DK DK12791143.6T patent/DK2780717T3/en active
- 2012-11-16 CN CN201280066354.5A patent/CN104067130B/zh active Active
- 2012-11-16 EP EP12791143.6A patent/EP2780717B1/en active Active
- 2012-11-16 US US14/358,147 patent/US9535060B2/en active Active
- 2012-11-16 US US13/679,294 patent/US9304127B2/en active Active
- 2012-11-16 MY MYPI2014001423A patent/MY174894A/en unknown
- 2012-11-16 ES ES12791143.6T patent/ES2617211T3/es active Active
- 2012-11-16 RU RU2014123987A patent/RU2657517C2/ru active
- 2012-11-16 RS RS20170258A patent/RS55804B1/sr unknown
- 2012-11-16 PT PT127911436T patent/PT2780717T/pt unknown
- 2012-11-16 SI SI201230877A patent/SI2780717T1/sl unknown
- 2012-11-16 US US13/679,281 patent/US9140696B2/en active Active
- 2012-11-16 JP JP2014541693A patent/JP6336911B2/ja active Active
2015
- 2015-03-24 HK HK15102988.3A patent/HK1202624A1/xx unknown
2017
- 2017-03-16 HR HRP20170427TT patent/HRP20170427T1/hr unknown
2023
- 2023-06-23 US US18/340,235 patent/US12228581B2/en active Active

Also Published As

Publication number	Publication date
US20130195874A1 (en)	2013-08-01
EP2780717B1 (en)	2016-12-21
ES2617211T3 (es)	2017-06-15
US9304127B2 (en)	2016-04-05
DK2780717T3 (en)	2017-02-13
PT2780717T (pt)	2017-02-16
EP2780717A1 (en)	2014-09-24
CN104067130A (zh)	2014-09-24
US20140322824A1 (en)	2014-10-30
MY174877A (en)	2020-05-20
US9140696B2 (en)	2015-09-22
MY178654A (en)	2020-10-20
RS55804B1 (sr)	2017-08-31
RU2657517C2 (ru)	2018-06-14
RU2014123987A (ru)	2015-12-27
JP6336911B2 (ja)	2018-06-06
SI2780717T1 (sl)	2017-05-31
JP2014533827A (ja)	2014-12-15
MY192113A (en)	2022-07-28
US20240085438A1 (en)	2024-03-14
US20130195875A1 (en)	2013-08-01
MY174894A (en)	2020-05-20
HUE032648T2 (en)	2017-10-30
CN104067130B (zh)	2017-02-22
US12228581B2 (en)	2025-02-18
MY175997A (en)	2020-07-20
WO2013072509A1 (en)	2013-05-23
US9535060B2 (en)	2017-01-03
HRP20170427T1 (hr)	2017-06-16
HK1202624A1 (en)	2015-10-02

Publication	Publication Date	Title
HK1202624A1 (en)	2015-10-02	Adrenomedullin assays and methods for determining mature adrenomedullin
HRP20180640T1 (hr)	2018-06-01	Anti-b7-h3 antitijelo
IL259826A (en)	2018-07-31	Anti-alphabetatisiar antibody
EP2751748A4 (en)	2016-06-15	METHOD AND ARRANGEMENTS FOR IDENTIFYING OBJECTS
GB201103955D0 (en)	2011-04-20	Antibodies
GB201112056D0 (en)	2011-08-31	Antibodies
EP2736330A4 (en)	2015-05-27	COMPOUNDS AND METHODS
EP2768983A4 (en)	2015-06-03	METHODS OF IDENTIFYING MUTATIONS ASSOCIATED WITH DISEASES
EP2747560A4 (en)	2015-02-25	CONNECTIONS AND METHODS
ZA201404319B (en)	2015-06-24	Biomarkers and parameters for preeclampsia
EP2736332A4 (en)	2015-03-18	CONNECTIONS AND METHODS
EP2637017A4 (en)	2014-10-15	METHOD FOR MEASURING FILLING CAPACITY
EP2736329A4 (en)	2015-03-25	COMPOUNDS AND METHODS
EP2700030A4 (en)	2016-05-18	DETERMINATION OF BORE INTEGRITY
ZA201306389B (en)	2015-03-25	Food analogs and methods for making food analogs
EP2791653A4 (en)	2015-09-30	PROCESS FOR OPTIMIZED SCATTEROMETRY
EP2685257A4 (en)	2014-10-01	METHOD OF ANALYSIS
GB201117538D0 (en)	2011-11-23	Methods
TWI563004B (en)	2016-12-21	Anti-hxcr1 antibody
AP2013007021A0 (en)	2013-07-31	Method for assaying hydrocarbons
IL228073A0 (en)	2013-09-30	Method for the determination of polysorbate
HK1259180A1 (zh)	2019-11-29	增加成骨細胞功能的方法
IL226429A0 (en)	2013-07-31	An in vitro method for determining the presence of type ii pyrethroids
EP2683996A4 (en)	2015-04-22	SYSTEMS AND PROCESSES FOR FERROUS ENHANCEMENT
EP2757373A4 (en)	2015-07-01	METHOD FOR MEASURING ANTI-WT1 ANTIBODIES